Kornimate/medical-research-clean huggingface dataset:
immunogenetic factors of coronary heart disease

Conditions: Cardiovascular Diseases; Coronary Disease; Heart Diseases; Hypertension; Obesity; Diabetes Mellitus; Hypothyroidism

Summary: to assess the association of immunogenetic factors with onset of coronary heart disease and the interrelationship of these factors with standard coronary heart disease risk factors.

background: although the familial clustering of coronary heart disease has been well documented, it is unclear as to whether the familial clustering can be explained by shared environmental factors by members of a family or by clustering of risk factors having a genetic component such as blood pressure, familial hyperlipidemia and/or diabetes. studies indicate that a family history of coronary disease may be an independent risk factor. major histocompatibility complex genetic markers to identify individuals at risk within a family may be useful. in 1985 when the study began, there was a paucity of data dealing with the interrelationship of family history, genetic markers, immunological markers, and traditional risk factors. design narrative: in this case-control study, the study population consisted of incident cases who presented to the georgia heart clinic in la grange, georgia with coronary heart disease. the majority of the subjects were from three counties in mideastern alabama and from counties in midwestern georgia. all subjects had undergone diagnostic coronary angiography. a determination was made in patients and controls of the association of major histocompatibility complex genetic markers hla-a, -b, -c, -dr, c4 and bf, c3, the restriction fragment length polymorphisms (rflp's) flanking the apolipoprotein ai and insulin genes, presence of autoantibodies, and family history of coronary disease, diabetes, or hypothyroidism. the frequency of these variables was compared with the standard coronary risk factors of family history, hypertension, lipid abnormalities, lifestyle, type a behavior, obesity and with diseases such as diabetes and hypothyroidism. an analysis was made of the strength of these variables for predicting those individuals at risk and whether there were variables which predict severity of disease based on 1, 2, or 3 vessel involvement. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
effects of prebiotic or probiotic supplements on symptoms of functional constipation

Conditions: Constipation

Summary: this study intends to evaluate the effects of three prebiotic solid beverages (mainly dietary fiber and prebiotics) and one probiotic solid beverage on the laxative effect of patients with functional constipation through randomized controlled trials. the influence of tract flora is expected to provide a basis for related therapies for patients with functional constipation.


Eligibility criteria:
inclusion criteria: 1. adults: 18 to 70 years old (not less than 50% of the final population over 45 years old, and not less than 30% of men); 2. patients with functional constipation (refer to rome iv diagnostic criteria for functional constipation); \* symptoms appeared for at least 6 months before diagnosis, and met the above diagnostic criteria in the past 3 months exclusion criteria: 1. pregnant and lactating women; 2. unable to take the test sample and complete the inspection items as required due to inability to take food by mouth, weakness, allergies or other reasons (including the inability to complete all items due to recent travel plans); 3. unclear main complaint and obvious abnormal mental state; 4. the liver and kidney function indexes are obviously abnormal (combined with the results of physical examination within the past 1 year); 5. acute gastrointestinal diseases occurred in the past month, and constipation caused by surgical operations in the past month; 6. take antibiotics, laxatives or topical agents, anticholinergics, antidiarrheals frequently in the past 1 month, and the frequency is more than 1 time/week 7. have been diagnosed with the following diseases: cancer (especially cancer of the digestive tract), severe enteritis, intestinal obstruction, inflammatory bowel disease, hypothyroidism, mental illness; 8. have been diagnosed with the following diseases: severe systemic diseases such as stroke, heart disease, liver cirrhosis, renal failure, hematopoietic system, or qualitative intestinal diseases caused by colonoscopy or imaging display; 9. in the past 3 months, there are often abdominal pain, abdominal pain accompanied by changes in bowel characteristics or frequency, blood in the stool, diarrhea or involuntary weight loss; 10. clinical manifestations or diseases that other researchers believe are not suitable for participating in the project.
a study to evaluate the depuy minimally invasive unicompartmental knee

Conditions: Osteoarthritis

Summary: the primary purpose of this investigation is to evaluate the surgical performance of the depuy minimally invasive (preservation) unicompartmental knee and instrumentation in a multi-centre setting. the secondary objective of this investigation is to evaluate the long-term survivorship of the depuy minimally invasive (preservation) unicompartmental knee.

primary endpoint - to demonstrate the suitability of the developed instrumentation to safely and accurately implant the preservation unicompartmental knee using postoperative radiographic limb and component alignment data. secondary endpoints - to demonstrate the survivorship and performance of the preservation unicompartmental knee using the american knee society clinical and radiological assessment, oxford knee score and survivorship analysis.

Eligibility criteria:
inclusion criteria: * male or female subjects, who are 40 to 75 years of age inclusive. * subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom written consent has been obtained. * subjects who, in the opinion of the investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups. * subjects who exhibit loss of articular cartilage which is predominantly confined to a single compartment. the remaining compartments must be intact and able to bear normal loads. * subjects who in the opinion of the clinical investigator are considered to be suitable for treatment with the investigation device, according to the indications specified in the package insert leaflet. exclusion criteria: * subjects who, in the opinion of the investigator, have an existing condition that would compromise their participation and follow-up in this study. * subjects with a known history of poor compliance to medical treatment. * women who are pregnant. * subjects who are known drug or alcohol abusers or with psychological disorders that could effect follow-up care or treatment outcomes. * subjects who have participated in a clinical study with an investigational product in the last month. * subjects who are currently involved in any injury litigation claims. * revision of an existing unicompartmental implant. * subjects who have gross ligament laxity / instability. * subjects who have an inflammatory joint disease * subjects in whom there is evidence of previous joint sepsis * subjects who have a pre-operative flexion contracture of 15° or greater * subjects who have a pre-operative flexion of less than 90° * subjects who have a pre-operative limb deformity of greater than 15° varus or valgus * subjects who have morbid obesity i.e. bmi \> 40%

Keywords: arthroplasty knee uka partial preservation
less invasive beractant administration in preterm infants

Conditions: Infant, Premature

Summary: the aim of this study is to assess the efficacy and feasibility of a new less invasive surfactant administration (lisa) technique with a specific designed cannula for surfactant administration using beractant replacement in preterm infants \<32 weeks of gestation and compare short and long term outcomes with the intubation, administration of surfactant and extubation method (insure). this was a single-center, prospective, open-label, non-randomized, controlled study with an experimental cohort of 30 patients treated with lisa and a retrospective control group comprising the 30 most recently treated patients with insure. beractant (4 ml/kg) was administered as exogenous surfactant in both groups if patients on nasal continuous positive airway pressure (ncpap) during the first three days of life were needed of more than 30% of fraction of inspired oxygen inspired oxygen fraction (fio2).


Eligibility criteria:
inclusion criteria: * preterm infants of less than 32 weeks of gestation (wg)breathing spontaneously on ncpap during the first three days of life that met exogenous surfactant administration criteria (table l) were eligible to enroll in the study exclusion criteria: * infants who met intubation criteria (table 1) at the moment of the surfactant administration were excluded in both groups.

Keywords: beractant feasibility studies infant, premature noninvasive ventilation
effects of speech-therapy in hypertensive patients

Conditions: Hypertension

Summary: anthroposophic speech therapy (ats) has been shown to positively influence heart rate variability (hrv) and heart rate - respiration coordination in healthy volunteers. this study was performed to learn more about such improvements and possible alteration in baroreflex sensitivity (brs) in hypertensive patients, which characteristically differ in those regulatory parameters from normotensive patients

in this prospective, primarily pre-post study, patients received three ats treatments in alternation with three control sessions (casual talking with the therapist). in order to perform hrv-analysis and brs determination blood pressure and ecg were continuously recorded during the sessions. changes in subjective well-being and perceived health were assessed by questionnaire before and after the various sessions (mood questionaire). thirty-one patients participated in this study, the majority diagnosed with arterial hypertension (22 out of 31).

Eligibility criteria:
inclusion criteria: * indication for speech therapy * willing and able to perform speech therapy * out-patient treatment or planned hospitalisation for at least 14 days. * diagnosed with hypertension (i 10, either on drug therapy or verified by 24h blood pressure measurements), with tension headache (g 44.2) or with anxiety (f 41) confirmed by the recruiting physician * no alteration in medication affecting hrv for the last 2 months before and during the study exclusion criteria: * comorbidity strongly influencing hrv * too weak to participate in an active therapy * pacemaker * skin disease or allergies preventing the use of ecg electrodes
impact of protein supplementation and resistance training on body composition, functional parameters, metabolic adaptation, and nitrogen balance in adults aged 45 years and older with overweight or obesity receiving incretin-based medications

Conditions: Obesity; Overweight (BMI &gt; 25); Weight Loss

Summary: this study aim to evaluate the effects of protein supplements and resistance training on body composition, functional parameters, metabolic adaptation, and nitrogen balance in adults (aged ≥45 years) with overweight/obesity receiving weekly incretin-based obesity management medication treatment for 6 months. a parallel design, open-label, multicenter randomized controlled trial will be conducted among 240 patients (aged ≥45 years) initiating incretin-based obesity management medication. participants will be recruited through obesity clinics at the tel-aviv sourasky medical center and the tel-aviv assuta medical center, obesity clinics of hmos, and social media groups. they will be randomly assigned to one of two groups in a 1:1 ratio: protein supplements ('easy whey' 25 gr protein/day) plus weekly resistance training and no intervention. data will be collected at baseline, 3, and 6 months, including demographics, medical status, body composition, functional parameters, resting metabolic rate, nitrogen balance, and physical activity performance. all participants will be advised to follow an exercise regime, a reduced-calorie diet based on the principle of the mediterranean eating pattern and be encouraged to follow a regular meeting schedule with a registered dietitian.


Eligibility criteria:
inclusion criteria: * adults aged ≥45 years. * overweight or obese (bmi ≥30, or bmi ≥27 with at least one obesity-related comorbidity). * eligible to receive incretin-based weight loss medications (e.g. wegovy or mounjaro). * able to read and speak hebrew fluently. exclusion criteria: * medical contraindications for incretin-based weight-loss medications. * current treatment with insulin or sulfonylurea medications. * inflammatory bowel disease. * active or unstable psychiatric disorders or cognitive impairment. * active bulimia nervosa. * previous bariatric surgery or bariatric endoscopic procedures. * use of other weight management medications within the past month. * weight loss of ≥5% within the past three months. * implanted cardiac pacemaker or other electronic implants. * regular resistance training within the past three months. * regular use of protein supplements. * allergy or intolerance to dairy proteins or vegan lifestyle.

Keywords: protein supplementation resistance training body composition metabolic rate nitrogen balance incretin-based medications wegovy mounjaro older adults obesity treatment
biological evolution of whipple's disease (whip)

Conditions: Whipple Disease

Summary: whipple's disease (wd), a rare systemic infection by tropheryma whipplei, lacks research on biological abnormalities pre- and post-treatment. this study explores these abnormalities for their diagnostic and monitoring value.

whipple's disease (wd) is a rare systemic infection caused by \*tropheryma whipplei\*. despite advancements in diagnosis through pcr and biopsy, there is limited research comparing biological abnormalities before and after treatment. this study aimed to characterize these abnormalities and evaluate their potential for aiding in diagnosis and monitoring.

Eligibility criteria:
inclusion criteria: * patients with at least one positive pcr test for whipple's disease and a retained diagnosis at brest university hospital between 2010 and 2024 * major patient exclusion criteria: * minors * no screening test for whipple's disease * opposition to participation * protected patients
outpatient treatment of low-risk venous thromboembolism with target specific anticoagulant

Conditions: Venous Thromboembolism

Summary: the objectives of this registry are to measure the outcomes, cost, adherence pattern and experience of patients treated as outpatients with rivaroxaban after being diagnosed with blood clots in the emergency department. the investigators hypothesize that patients will have a relatively low rate of adverse events and higher adherence than has been reported historically for warfarin treatment. patients will be scheduled for follow up care with one of dr. kline's outpatient thrombosis clinics at methodist hospital, eskenazi health services and the baylor university medical center (dallas, tx) after diagnosis and treatment of pulmonary embolism (pe) or deep vein thrombosis (dvt).

information will be obtained from the patient medical records, past medical history, physical examination at initial outpatient clinic visit 30 days (+/- 14 days) and 6 months or 180 days (+/- 14 days) post diagnosis or start of treatment, then annual follow ups for up to 5 years. the data will be collected and stored in a database, the iu redcap database system will be used to develop a database and store information .

Eligibility criteria:
inclusion: * dvt or pe diagnosed on imaging: * systolic always\>100 mm hg in absence of history of low blood pressure * no contraindication to anticoagulation treatment (active bleeding or high risk postoperative status, creatinine clearance \< 30 ml/min, history of heparin induced thrombocytopenia or warfarin skin necrosis); * no other medical condition requiring hospital treatment (sepsis, new or decompensated existing organ failure, intractable pain); * no social condition requiring hospital treatment (homelessness with history of non-adherence to treatment, suspected neglect or abuse, incarceration, untreated psychosis, severe alcohol or drug dependency); * no coagulopathy or current anticoagulant resulting in an inr\>1.7, or thrombocytopenia (platelet count \< 50,000/ul); * no need for supplemental oxygen (no respiratory distress and pulse ox always \>94%) exclusion: - if active cancer, pompe-c \<6%

Keywords: patient compliance target specific anticoagulant quality of life
evaluation of the efficacy of ropivacaine in children and young adults with hereditary epidermolysis bullosa

Conditions: Epidermolysis Bullosa

Summary: the purpose of this study is to determine whether topical application of ropivacaine is effective for treating refractory pain during dressing changes and so improve quality of life of patients (newborn, child, adolescent or adults under 21) suffering from hereditary epidermal epidermolysis bullosa.

this clinical trial aims to determine the efficacy on pain of local application of ropivacaine 0.2% on cutaneous lesions related to epidermolysis bullosa during dressing change, associated with the standard premedication. patients will be hospitalized and will have several baths. the first bath will be done according to usual protocol (usual premedication 1h before the bath). pain measurements (visual analog scale or flacc) will be done at the entry into the water, in the middle of bath and at the time of the dressing change. the following baths will be done using local application of ropivacaine 15 minutes before entering into the water on lesions identified by the patients as the most painful lesions due to epidermolysis bullosa. a blood test will be done during the first use of ropivacaine to determine plasmatic level of ropivacaine. after 3 baths in the dermatology unit, patients will continue such bath at home, every 48h during 15 days.

Eligibility criteria:
inclusion criteria: * minor patient or adult ≤ 21 years of age with hereditary epidermolysis bullosa, * presenting pain at the entrance of the bath with an average of eva or flacc greater than 4/10 the week before the inclusion * usually requiring premedication with weak or strong opioid * parental consent if minor or patient consent * affiliated with social security exclusion criteria: * patient with a known allergy to ropivacaine or other local anesthetics with amide binding or one of the excipients mentioned in the spc * severe renal insufficiency defined by dfg below 29ml / min * moderate to severe hepatic insufficiency defined by a child-pugh b or c score and ast or alat greater than 3 times normal * moderate to severe cardiac failure defined by fegv less than 45% and/or nyha class ii to iv * hypovolemia

Keywords: hereditary epidermolysis bullosa pain bath dressing change ropivacaine topical application
application of surgical navigation system in sentinel lymph node of breast cancer research

Conditions: Sentinel Lymph Node; Breast Cancer

Summary: the purpose of this study is to compare the sentinel lymph node (sln) detection rate of early breast cancer patients between using indocyanine green (icg) and methylene blue with a novel surgical navigation system.

assessment of the sentinel lymph node (sln) in patients with early stage breast cancer is vital in selecting the appropriate surgical approach. however, the existing methods, including methylene blue and nuclides, possess low efficiency and effectiveness in mapping slns, and to a certain extent exert side effects during application. indocyanine green (icg), as a fluorescent dye, has been proved reliable usage in sln detection by several other groups. in this paper, the investigators introduce a novel surgical navigation system to detect sln with icg. this system contains two charge-coupled devices (ccd) to simultaneously capture real-time color and fluorescent video images through two different bands. during surgery, surgeons only need to follow the fluorescence display. in addition, the system saves data automatically during surgery enabling surgeons to find the registration point easily according to image recognition algorithms. the investigators aim to show that the usage of our surgical navigation system with icg to detect slns in breast cancer patients is technically feasible.

Eligibility criteria:
inclusion criteria: (before the test, all the subjects required for meeting the entry requirements before they join the group) * female patients; * the preoperative core needle biopsy or open surgical excision biopsy diagnosis as breast cancer; * tumor diameter ≤ 3cm; * no clinical examination of suspicious axillary lymph node-positive; * diagnosed clinical conditions can be directly surgery as i, ii breast cancer patients; * preoperative clinical or radiologic evidence without distant metastases (m0); * signed informed consent. exclusion criteria: (before the test, the subjects under any one of items to meet the requirements can not be enrolled) * sentinel lymph node biopsy history had received surgery or axillary area; * multi-center breast cancer or multiple lesions; * clinical axillary lymph node metastasis have been found; * mammary area had received neoadjuvant chemotherapy or radiotherapy; * inflammatory breast cancer; * pregnancy; * no personal freedom and independent civil capacity. exclusion criteria: (trials, subjects necessary to meet the requirements of any one item, exit the clinical trial research.) * severe allergic reaction occurs; * persistent allergic reaction; * subjects were required to withdraw from a clinical trial; * researchers consider it not appropriate to continue to participate in the clinical trial investigator.

Keywords: near-infrared fluorescence image guided surgery breast cancer; sentinel lymph node biopsy indocyanine green methylene blue